Visual recovery comes after anatomical recovery after intravitreal aflibercept treatment in macular edema secondary to branch retinal vein occlusion

Bayat, Alper Halil; Erden, Burak; Çakir, Akın; Özturan, Şeyma Gülcenur; Bölükbaşı, Selim; Elçioğlu, Mustafa Nuri

doi:10.5455/medscience.2018.07.8854

Cited by 1 publication

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average age of these patients ranged from 68.7 to 70.1 years, and their baseline BCVA letters ranged from 45.9 to 54.1. There were five RWSs [ 1 , 30 – 33 ], with patients from Sweden, England, Turkey, Greece, the USA, Switzerland, Australia, and France. Patients were treatment-naïve at baseline and the total sample size was 722, including groups ranging from 34 to 291 in number.…”

Section: Resultsmentioning

confidence: 99%

“…Patients were treatment-naïve at baseline and the total sample size was 722, including groups ranging from 34 to 291 in number. One RWS [ 32 ] reported the median age as being 74 and 76 years in the two groups, respectively, and another four trials [ 1 , 30 , 31 , 33 ] reported that the average age ranged from 61.2 to 73 years. Four RWSs [ 1 , 30 , 31 , 33 ] reported that the average baseline of BCVA letters ranged from 28 to 65.3.…”

Section: Resultsmentioning

confidence: 99%

“…One RWS [ 32 ] reported the median age as being 74 and 76 years in the two groups, respectively, and another four trials [ 1 , 30 , 31 , 33 ] reported that the average age ranged from 61.2 to 73 years. Four RWSs [ 1 , 30 , 31 , 33 ] reported that the average baseline of BCVA letters ranged from 28 to 65.3. In one study, only non-ischemic cases were included [ 1 ].…”

Section: Resultsmentioning

confidence: 99%

“…The other two studies did not report the type of ischemia in patients [ 28 , 32 ]. Other studies involved a mixed population of patients with ischemic or non-ischemic CRVO [ 29 – 31 , 33 ] (Supplementary Materials Table S2 ).…”

Section: Resultsmentioning

confidence: 99%

“…The NOS results for RWSs indicated that, in the category of selection, one study [ 1 ] received a score of 3, with the exception of a score of zero in the item of selection of the non-exposed cohort, and other studies got a score of 4; in the category of comparability, all studies received a score of 1; in the category of outcome, three studies [ 30 , 38 , 39 ] received a score of 2, with the exception of a score of zero in the item of completeness of follow-up and other studies received a score of 3. Seven studies [ 31 – 33 , 35 – 37 , 40 ] received a total score of 8, while four studies [ 1 , 30 , 38 , 39 ] received a score of 7. All included studies were of high quality (Supplementary Materials Table S8 and Table S9 ).…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis

Wu,

He,

et al. 2024

Ophthalmol Ther

View full text Add to dashboard Cite

Introduction This systematic review and meta-analysis aimed to provide an updated evidence base for clinical decision-making by comparing the efficacy and safety of aflibercept 2 mg and ranibizumab in treating retinal vein occlusion (RVO). Methods A systematic search was conducted using eight databases up to December 2021. Randomized controlled trials (RCTs) and real-world studies (RWSs) comparing aflibercept and ranibizumab in patients with RVO were evaluated. The primary outcomes assessed were efficacy, number of injections administered, and adverse events. Results Three RCTs (424 patients) and 11 RWSs (1415 patients) were included. For central RVO (CRVO), RCTs demonstrated a comparable efficacy, whereas RWSs showed that mean changes from baseline in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were significantly greater with aflibercept compared to ranibizumab; the number of injections of aflibercept was fewer than that of ranibizumab in RCTs, but similar in RWSs. For branch RVO (BRVO), no statistically significant difference in efficacy between the two drugs in RCTs/RWSs was observed, with fewer injections of aflibercept at 12 months in RWSs. The safety profiles of both drugs were similar for both CRVO and BRVO. Conclusions For CRVO, aflibercept had similar efficacy and safety profile but with fewer injections versus ranibizumab in RCTs; RWSs showed greater BCVA improvement and CRT reduction with aflibercept than ranibizumab. For BRVO, RCTs showed similar in efficacy, safety, and injection numbers for both drugs, while RWSs demonstrated that aflibercept required fewer injections at 12 months of follow-up. Overall, this study provides updated evidence for clinical decision-making in the treatment of RVO. Supplementary Information The online version contains supplementary material available at 10.1007/s40123-024-00915-0.

show abstract

Section: Resultsmentioning

confidence: 99%